PYRIDOXAMINE FOR THE TREATMENT OF SICKLE CELL DISEASE, THALASSEMIA AND RELATED BLOOD DISEASES
申请人:NANOMETICS LLC
公开号:US20170056381A1
公开(公告)日:2017-03-02
The present invention relates to treatments and therapies for anemia conditions and diseases of the blood, and more particular is a therapy for the acute and chronic treatment of sickle cell diseases and thalassemia by administration of pyridoxamine, or a pharmaceutically acceptable salt thereof, optionally in combination with an additional bioactive agent.